Schonfeld Strategic Advisors LLC Aveo Pharmaceuticals, Inc. Transaction History

Schonfeld Strategic Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.48 - $14.97 $4.93 Million - $8.7 Million	580,848 Added 606.48%	676,621 $10.1 Million
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $1.32 Million - $1.75 Million	-200,183 Reduced 67.64%	95,773 $788,000
Q2 2022 Aug 15, 2022	BUY	$3.51 - $6.67 $224,766 - $427,120	64,036 Added 27.61%	295,956 $1.94 Million
Q1 2022 May 16, 2022	BUY	$3.15 - $6.01 $730,548 - $1.39 Million	231,920 New	231,920 $1.3 Million
Q1 2021 May 17, 2021	SELL	$5.97 - $15.28 $66,864 - $171,136	-11,200 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.08 - $6.68 $56,896 - $74,816	11,200 New	11,200 $65,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.